

Adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review and meta-synthesis of the qualitative literature using grounded theory

Supportive Care in Cancer

Othman AlOmeir*; Nilesh Patel; Parastou Donyai

* Corresponding author: Othman AlOmeir, Department of Pharmacy, University of Reading, PO Box 226, Whiteknights, Reading, Berkshire RG6 6AP, UK. E-mail:

o.k.o.alomeir@pgr.reading.ac.uk; Telephone number: +44 (0)118 378 4704

Online Resource 8: Quality assessment of the studies included in the review based on Hawker et al.*

Study	Abstract and title (1)	Introduction and aims (2)	Method and data (3)	Sampling (4)	Data analysis (5)	Ethics and bias (6)	Findings/ results (7)	Transferability/ generalizability (8)	Implications and usefulness (9)	Total
Harrow et al. 2014 [1]	g	f	g	g	g	vp	g	g	g	g = 7 f = 1 vp = 1
Wei et al. 2017 [2]	g	p	g	p	g	p	g	g	f	g = 5 f = 1 p = 3
Van Londen et al. 2014 [3]	g	f	f	g	g	vp	g	g	f	g = 5 f = 3 vp = 1
Wells et al. 2016 [4]	g	g	f	g	f	vp	g	g	g	g = 7 f = 1 vp = 1
Iacorossi et al. 2016 [5]	g	g	g	g	g	g	g	g	g	g = 9
Bourmaud et al. 2016 [6]	g	f	f	g	g	p	g	g	f	g = 5 f = 3 p = 1
Flanagan et al. 2016 [7]	g	f	g	g	g	g	g	g	f	g = 7 f = 2
Rust and Davis 2011 [8]	f	g	g	g	g	vp	g	f	p	g = 5 f = 2 p = 1 vp = 1

Xu and Wang, 2019 [24]	g	p	f	p	g	f	g	f	f	g=3 f=4 p=2
---------------------------	---	---	---	---	---	---	---	---	---	-------------------

(1) Abstract and title: Did they provide a clear description of the study? **(2) Introduction and aims:** Was there a good background and clear statement of the aims of the research? **(3) Method and data:** Is the method appropriate and clearly explained? **(4) Sampling:** Was the sampling strategy appropriate to address the aims? **(5) Data analysis:** Was the description of the data analysis sufficiently rigorous? **(6) Ethics and bias:** Have ethical issues been addressed, and what has necessary ethical approval gained? Has the relationship between research and participants been adequately considered? **(7) Results:** Is there a clear statement of the findings? **(8) Transferability or generalizability:** Are the findings of this study transferable (generalizable) to a wider population? **(9) Implications and usefulness:** How important are these findings to policy and practice? **Criteria:** g = good; f = fair; p = poor; vp = very poor.

Full references of the included studies

1. Harrow A, Dryden R, McCowan C, et al (2014) A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer. *Bmj Open* 4:e005285. <https://doi.org/10.1136/bmjopen-2014-005285>
2. Wei C, Nengliang Y, Yan W, et al (2017) The patient-provider discordance in patients' needs assessment: a qualitative study in breast cancer patients receiving oral chemotherapy. *J Clin Nurs* 26:125–132. <https://doi.org/10.1111/jocn.13374>
3. van Londen GJ, Donovan HS, Beckjord EB, et al (2014) Perspectives of Postmenopausal Breast Cancer Survivors on Adjuvant Endocrine Therapy-related Symptoms. *Oncol Nurs Forum* 41:660–668. <https://doi.org/10.1188/14.ONF.660-668>
4. Wells KJ, Pan TM, Vázquez-otero C, et al (2016) Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study. *Support Care Cancer Heidelb* 24:4123–4130. <http://dx.doi.org/10.1007/s00520-016-3229-8>
5. Iacorossi L, Gambalunga F, Fabi A, et al (2016) Adherence to Oral Administration of Endocrine Treatment in Patients With Breast Cancer: A Qualitative Study. *Cancer Nurs*. <https://doi.org/10.1097/NCC.0000000000000452>
6. Bourmaud A, Rousset V, Regnier-Denois V, et al (2016) Improving Adherence to Adjuvant Endocrine Therapy in Breast Cancer Through a Therapeutic Educational Approach: A Feasibility Study. *Oncol Nurs Forum Pittsburgh* 43:E94–E103. <http://dx.doi.org/10.1188/16.ONF.E94-E103>
7. Flanagan J, Tetler D, Winters L, et al (2016) The Experience of Initiating Oral Adjuvant Treatment for Estrogen Receptor-Positive Breast Cancer. *Oncol Nurs Forum* 43:E143–E152. <https://doi.org/10.1188/16.ONF.E143-E152>

8. Rust C, Davis C (2011) Health literacy and medication adherence in underserved African-american breast cancer survivors: a qualitative study. *Soc Work Health Care* 50:739–761. <https://doi.org/10.1080/00981389.2011.585703>
9. Pellegrini I, Sarradon-Eck A, Ben Soussan P, et al (2010) Women's perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients' point of view. *Psychooncology* 19:472–479. <https://doi.org/10.1002/pon.1593>
10. Adams N, Gisiger-Camata S, Hardy CM, et al (2017) Evaluating Survivorship Experiences and Needs Among Rural African American Breast Cancer Survivors. *J Cancer Educ Off J Am Assoc Cancer Educ* 32:264–271. <https://doi.org/10.1007/s13187-015-0937-6>
11. Wickersham K, Happ MB, Bender CM (2012) "Keeping the Boogie Man Away": Medication Self-Management among Women Receiving Anastrozole Therapy. *Nurs Res Pract* 2012:462121. <https://doi.org/10.1155/2012/462121>
12. Farias AJ, Ornelas IJ, Hohl SD, et al (2017) Exploring the role of physician communication about adjuvant endocrine therapy among breast cancer patients on active treatment: a qualitative analysis. *Support Care Cancer Off J Multinatl Assoc Support Care Cancer* 25:75–83. <https://doi.org/10.1007/s00520-016-3389-6>
13. Wouters H, van Geffen ECG, Baas-Thijssen MC, et al (2013) Disentangling breast cancer patients' perceptions and experiences with regard to endocrine therapy: nature and relevance for non-adherence. *Breast Edinb Scotl* 22:661–666. <https://doi.org/10.1016/j.breast.2013.05.005>
14. Brauer ER, Ganz PA, Pieters HC (2016) "Winging It": How Older Breast Cancer Survivors Persist With Aromatase Inhibitor Treatment. *J Oncol Pract* 12:e991–e1000. <https://doi.org/10.1200/JOP.2016.011767>
15. Cahir C, Dombrowski SU, Kelly CM, et al (2015) Women's experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour. *Support Care Cancer* 23:3115–3130. <https://doi.org/10.1007/s00520-015-2685-x>
16. Cheng H, Sit JWH, Cheng KKF (2017) A qualitative insight into self-management experience among Chinese breast cancer survivors. *Psychooncology* 26:1044–1049. <https://doi.org/10.1002/pon.4279>
17. Verbrugghe M, Verhaeghe S, Decoene E, et al (2017) Factors influencing the process of medication (non-)adherence and (non-)persistence in breast cancer patients with adjuvant antihormonal therapy: a qualitative study. *Eur J Cancer Care (Engl)* 26:. <https://doi.org/10.1111/ecc.12339>

18. Moon Z, Moss-Morris R, Hunter MS, Hughes LD (2017) Understanding tamoxifen adherence in women with breast cancer: A qualitative study. *Br J Health Psychol* 22:978–997. <https://doi.org/10.1111/bjhp.12266>
 19. Brett J, Boulton M, Fenlon D, et al (2018) Adjuvant endocrine therapy after breast cancer: a qualitative study of factors associated with adherence. *Patient Prefer Adherence* 12:291–300. <https://doi.org/10.2147/PPA.S145784>
 20. Bluethmann SM, Murphy CC, Tiro JA, et al (2017) Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study. *Oncol Nurs Forum* 44:E101–E110. <https://doi.org/10.1188/17.ONF.E101-E110>
 21. Humphries B, Collins S, Guillaumie L, et al (2018) Women’s Beliefs on Early Adherence to Adjuvant Endocrine Therapy for Breast Cancer: A Theory-Based Qualitative Study to Guide the Development of Community Pharmacist Interventions. *Pharmacy* 6:53. <https://doi.org/10.3390/pharmacy6020053>
 22. Karlsson SA, Wallengren C, Bagge RO, Hénoc I “It is not just any pill” —Women’s experiences of endocrine therapy after breast cancer surgery. *Eur J Cancer Care (Engl)* 0:e13009. <https://doi.org/10.1111/ecc.13009>
 23. Lambert LK, Balneaves LG, Howard AF, et al (2018) Understanding adjuvant endocrine therapy persistence in breast Cancer survivors. *BMC Cancer* 18:. <https://doi.org/10.1186/s12885-018-4644-7>
 24. Xu L, Wang A (2019) Health belief about adjuvant endocrine therapy in premenopausal breast cancer survivors: a qualitative study. *Patient Prefer Adherence* 13:1519–1525. <https://doi.org/10.2147/PPA.S217562>
- * Hawker S, Payne S, Kerr C, et al (2002) Appraising the Evidence: Reviewing Disparate Data Systematically. *Qual Health Res* 12:1284–1299. <https://doi.org/10.1177/1049732302238251>